← Back
Data updated: Jun 28, 2026
HAMELN RDS GMBH
Generics Pharmaceuticals
HAMELN RDS GMBH is a generic drug manufacturer with 1 FDA-approved products.
2012
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
HAMELN RDS GMBH's Key Drugs
HAMELN RDS GMBH's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
No active drugs
HAMELN RDS GMBH's Recent FDA Approvals
New NDA/BLA approvals for HAMELN RDS GMBH over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
HAMELN RDS GMBH's Therapeutic Areas
Disease areas where HAMELN RDS GMBH has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
HAMELN RDS GMBH Pipeline Snapshot
Active clinical trials for HAMELN RDS GMBH across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2012-09-10
- Latest
- 2012-09-10
- Applications
- 1